Incidence and prognostic impact of KRAS and BRAF mutations in patients undergoing liver surgery for colorectal metastases.

Authors

null

Georgios Karagkounis

The Johns Hopkins University School of Medicine, Baltimore, MD

Georgios Karagkounis , Michael S. Torbenson , Hubert D Daniel , Nilofer Saba Azad , Luis A. Diaz Jr., Ross C. Donehower , Kenzo Hirose , Timothy M. Pawlik , Michael A. Choti

Organizations

The Johns Hopkins University School of Medicine, Baltimore, MD, The Johns Hopkins Hospital, Baltimore, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD

Research Funding

No funding sources reported
Background: Molecular biomarkers offer the potential for refining prognostic determinants in patients undergoing cancer surgery. Among patients with colorectal cancer metastases, KRAS and BRAF are important biomarkers, but their role in patients undergoing surgical therapy for liver metastases is unknown. In this study, the prevalence and prognostic significance of KRAS and BRAF mutations were determined in patients undergoing surgical therapy of colorectal liver metastases (CRLM). Methods: KRAS and BRAF analysis was performed on 202 patients undergoing curative intent surgical therapy of CRLM between 2003 and 2008. Tumor samples were analyzed for somatic mutations using sequencing analysis (KRAS: codon 12/13, BRAF: V600E). The frequency of mutations was ascertained and their impact on outcome determined relative to other clinicopathologic factors. Results: KRAS gene mutations were detected in 58/202 patients (29%) undergoing surgery for CRLM, comparable to that reported in non-surgical patient series. In contrast, mutation in the BRAF gene was identified in very low frequency in this surgical cohort, found in only 4/202 (2%) patients. KRAS mutations were associated with worse long-term survival (HR=2.13, CI=1.25-3.65), as well as risk of recurrence (HR=1.89, CI=1.12-3.19). ). In addition, KRAS mutation was also associated with risk of recurrence following surgical therapy (HR=1.89, CI=1.12-3.19).While other clinicopathologic features, including tumor number, CEA and primary stage were also associated with survival, KRAS status remained independently predictive of outcome. The low incidence of BRAF mutation limited the ability to determine its prognostic impact. Conclusions: While KRAS mutations were found in approximately one third of patients, BRAF mutations were found in only 2% of patients undergoing surgery for CRLM. KRAS status was an independent predictor of overall and disease-free survival. Molecular biomarkers such as KRAS may help to refine our prognostic assessment of patients undergoing surgical therapy for CRLM.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Citation

J Clin Oncol 30, 2012 (suppl; abstr 3616)

DOI

10.1200/jco.2012.30.15_suppl.3616

Abstract #

3616

Poster Bd #

36E

Abstract Disclosures

Similar Abstracts

Abstract

2022 ASCO Gastrointestinal Cancers Symposium

Clinical evolution after surgery of hepatic metastases of colorectal cancer according to genomic profile.

First Author: Blanca Morón García

Abstract

2023 ASCO Gastrointestinal Cancers Symposium

Mutation status of full RAS and BRAF in 169 Moroccan patients with colorectal cancer.

First Author: Sara El Zaitouni

Abstract

2023 ASCO Gastrointestinal Cancers Symposium

Circulating tumor DNA–based genomic landscape of KRAS wild-type pancreatic adenocarcinoma.

First Author: Brendon Fusco